People with a rare form of eye cancer will have access to a “pioneering” drug on the NHS which extends survival chances by almost 10 per cent, officials have announced.
Tebentafusp – sold under the brand name Kimmtrak – is the first treatment of its kind for uveal melanoma, which develops from cells in the middle layer of the eye, known as the uvea.
